Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma
Biomolecules · 2024
DOI: 10.3390/biom15010017 ↗Kurz gefasst
Fallbericht in der Zeitschrift Biomolecules, 2024. Verfasst von Ilham Badrane und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy. Hauptthemen laut MEDLINE: Adenocarcinoma, Prostatic Neoplasms, Racemases and Epimerases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer (PCa) is a high-prevalence disease usually characterized by metastatic spread to the pelvic lymph nodes and bones and the development of visceral metastases only in the late stages of disease. Positron Emission Tomography (PET) plays a key role in the detection of PCa metastases. Several PET radiotracers are used in PCa patients according to the stage and pathological features of the disease, in particular 68Ga/18F-prostate-specific membrane antigen (PSMA) ligands. Moreover, 2-deoxy-2-[18F]fluoro-D-glucose 18F-FDG PET usually shows metastases in the late stages of disease, when dedifferentiated neoplastic clones lose PSMA expression. In some cases, PCa patients may present atypical sites of metastases, with uncommon appearance at PET imaging with different radiotracers. We present the case of a patient with biochemical recurrence of PCa (ISUP Grade Group IV; PSA 4.7 ng/mL) showing atypical sites of metastases (the testis and multiple lung nodules) with absent PSMA expression and high [18F]FDG avidity. The patient showed diffuse positivity to alpha-methylacyl-coenzyme A racemase (AMACR). Moreover, a literature review was performed by collecting cases of PCa patients with atypical metastatic spread detected via PET imaging, with the aim of highlighting the relationship between atypical sites of metastases, imaging presentation, and pathology findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy.
- Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.
- Nuclear Medicine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Department of Pathology and Diagnostic Health, University of Verona, 37100 Verona, Italy.
- Anatomic Pathology Unit, University Hospital of Ferrara, 44124 Ferrara, Italy.
- Oncology Unit, University Hospital of Ferrara, 44124 Ferrara, Italy.
ORCID-Profile: Corrado Cittanti, Massimo Castellani, Licia Uccelli, Luca Urso
Zitieren
APA
Badrane, I., Castello, A., Brunelli, M., Cittanti, C., Adamantiadis, S., Bagni, I., Mindicini, N., Lancia, F., Castellani, M., Uccelli, L., Bartolomei, M., & Urso, L. (2024). Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma. Biomolecules. https://doi.org/10.3390/biom15010017
Vancouver
Badrane I, Castello A, Brunelli M, Cittanti C, Adamantiadis S, Bagni I, et al. Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma. Biomolecules. 2024. doi:10.3390/biom15010017
BibTeX
@article{Badrane2024,
author = {Badrane, Ilham and Castello, Angelo and Brunelli, Matteo and Cittanti, Corrado and Adamantiadis, Sara and Bagni, Ilaria and Mindicini, Noemi and Lancia, Federica and Castellani, Massimo and Uccelli, Licia and Bartolomei, Mirco and Urso, Luca},
title = {Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom15010017}
}
EUVIMED